The Globe and Mail

Go to the Globe and Mail homepage

Jump to main navigationJump to main content

AdChoices
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $5.86

Today's change0.00 0.00%
Updated May 27 4:00 PM -4GMT. Delayed by at least 15 minutes.
 

Keryx Biopharmaceuticals Inc

Nasdaq: KERX
Last

(U.S.) $5.86

Today's change0.00 0.00%
Updated May 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Keryx Biopharmaceuticals Inc closed at (U.S.)$5.86.

Over the last five days, shares have gained 2.09% and 16.04% year to date. Shares have underperformed the S&P 500 by 42.10% during the last year.

Key company metrics

  • Open(U.S.) $0.00
  • Previous close(U.S.) $5.86
  • High--
  • Low--
  • Bid / Ask(U.S.) $5.57 / (U.S.) $5.91
  • YTD % change+16.04%
  • Volume0
  • Average volume (10-day)1,034,370
  • Average volume (1-month)1,355,954
  • Average volume (3-month)1,631,974
  • 52-week range(U.S.) $2.80 to (U.S.) $10.80
  • Beta4.07
  • Trailing P/ENegative, not meaningful
  • P/E 1 year forwardNegative, not meaningful
  • Forward PEGNegative, not meaningful
  • Indicated annual dividend--
  • Dividend yield0.00%
  • Trailing EPS(U.S.) -$1.30
Updated May 27 4:00 PM -4GMT. Delayed by at least 15 minutes.

Profit

Net Profit (TTM)
-705.48%

Although this company's net profit margin is negative, it is above the industry average and implies that Keryx Biopharmaceuticals Inc is operating more effectively than other companies in the industry.
Company Books

S&P TSX0.00%Sector:HealthcareIndustry:Biotechnology
  • Income Statement
  • Balance Sheet
  • Cash Flow
Quarter | Annual
Q1/2016Q4/2015Q3/2015Q2/2015
Fiscal Quarter Endvalues in (U.S.) $ millions unless otherwise notedMar 31, 201603/31/2016Dec 31, 201512/31/2015Sep 30, 201509/30/2015Jun 30, 201506/30/2015
Revenue7643
Total other revenue--------
Total revenue7643
Gross profit5412
Total cost of revenue2241
Total operating expense30313529
Selling / general / administrative21222021
Research & development88118
Depreciation / amortization--------
Interest expense (income), net operating--------
Unusual expense (income)--------
Other operating expenses, total--------
Operating income-23-25-31-27
Interest income (expense), net non-operating--------
Gain (loss) on sale of assets--------
Other--------
Income before tax-41-38-31-27
Income after tax-41-38-31-27
Income tax, total0000
Net income-41-38-31-27
Total adjustments to net income--------
Net income before extra. items-41-38-31-27
Minority interest--------
Equity in affiliates--------
U.S. GAAP adjustment--------
Inc. avail. to common excl. extra. items-41-38-31-27
Inc. avail. to common incl. extra. items-41-38-31-27
Diluted net income-41-38-31-27
Dilution adjustment--0----
Diluted weighted average shares106105105105
Diluted EPS excluding extraordinary itemsvalue per share-0.39-0.36-0.29-0.26
Dividends per sharevalue per share0.000.000.000.00
Diluted normalized EPSvalue per share-0.39-0.36-0.29-0.26
R